New Archive Blog - Treehill Partners

News & Views

October 1, 2024

European Immunology M&A Flares Up As Big Pharma Seeks Next Blockbuster – Ali Pashazadeh, Treehill’s CEO gives key insights for article in Mergermarket’s Snapshot series.

Posted By: TreehillPartners
In: Dealmaking

Ali Pashazadeh, Treehill’s CEO, contributes to an article in Mergermarket summarising current trends in the European immunology, inflammatory and autoimmune marketplaces...

September 30, 2024

Biotech Course Correction – BioProcess Online podcast with Treehill Partners CEO Ali Pashazadeh

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets...

August 30, 2024

Long-term perspectives on new drug classes – Ali Pashazadeh, Treehill Partners CEO, quoted in Endpoints News

Posted By: TreehillPartners
In: Drug Development

Using a mechanistic pathway or agent to achieve something else than it was designed to do, leaves questions unanswered that will become clear only over time...

July 19, 2024

Too Much Data: a Burden or a Blessing? – Clinical Trials Arena Article Quote

Posted By: TreehillPartners
In: Drug Development

July 18, 2024

Who Is Driving The Bus?

Posted By: TreehillPartners
In: Drug Development

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News & Views

European Immunology M&A Flares Up As Big Pharma Seeks Next Blockbuster – Ali Pashazadeh, Treehill’s CEO gives key insights for article in Mergermarket’s Snapshot series.

Biotech Course Correction – BioProcess Online podcast with Treehill Partners CEO Ali Pashazadeh

Long-term perspectives on new drug classes – Ali Pashazadeh, Treehill Partners CEO, quoted in Endpoints News

Too Much Data: a Burden or a Blessing? – Clinical Trials Arena Article Quote

Who Is Driving The Bus?

The Medicine Maker – Ali Pashazadeh on the Bottlenecks Slowing Drug Development

The Medicine Maker Power List 2026 – Treehill Partners CEO Named Among the Most Influential Voices in Biopharma

The Real Questions Behind the GLP-1 Boom